Progress on treatment of tachyarrhythmia in infants
10.3760/cma.j.issn.1673-4912.2022.04.015
- VernacularTitle:婴幼儿快速性心律失常治疗进展
- Author:
Ziyan DONG
1
;
Zhen ZHEN
;
Lu GAO
;
Li LIN
;
Lang CUI
;
Wei SHAO
;
Xia YU
;
Yue YUAN
Author Information
1. 首都医科大学附属北京儿童医院心脏内科 100045
- Keywords:
Tachyarrhythmia;
Infants;
Treatment
- From:
Chinese Pediatric Emergency Medicine
2022;29(4):312-316
- CountryChina
- Language:Chinese
-
Abstract:
Infant tachycardia is a critical disease, mainly with supraventricular tachycardia and ventricular tachycardia.The treatment of tachycardia in infant is quite different from that of older children, and there is no relevant guidelines at present.Drug therapy in the acute stage of supraventricular tachycardia and atrial fluttery is mainly intravenous adenosine injection.Digoxin is widely used in neonates.Propranolol is the first choice for prophylactic treatment, and landilolol is in the development stage.Ventricular tachycardia can be spontaneously subsided, the treatment is dominated by intravenous lidocaine.For non-drug therapy, heart cardioerter is the emergency treatment for serious rapid arrhythmia.Radiofrequency ablation is used in infants with more severe conditions and where the onset of tachycardia can not be controlled.Bury cardioverter-defibrillator is effective in preventing infant ion channel disease complicated with malignant ventricular tachycardia induced sudden cardiac death.Subcutaneous implantion of a defibrillator may be superior to intravenous implantation in infants and young children.
